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Abstract
Introduction: Ventilator-associated pneumonia (VAP) may contribute to the mortality associated with acute
respiratory distress syndrome (ARDS). We aimed to determine the incidence, outcome, and risk factors of bacterial
VAP complicating severe ARDS in patients ventilated by using a strictly standardized lung-protective strategy.
Methods: This prospective epidemiologic study was done in all the 339 patients with severe ARDS included in a
multicenter randomized, placebo-controlled double-blind trial of cisatracurium besylate in severe ARDS patients.
Patients with suspected VAP underwent bronchoalveolar lavage to confirm the diagnosis.
Results: Ninety-eight (28.9%) patients had at least one episode of microbiologically documented bacterial VAP,
including 41 (41.8%) who died in the ICU, compared with 74 (30.7%) of the 241 patients without VAP (P = 0.05).
After adjustment, age and severity at baseline, but not VAP, were associated with ICU death. Cisatracurium besylate
therapy within 2 days of ARDS onset decreased the risk of ICU death. Factors independently associated with an
increased risk to develop a VAP were male sex and worse admission Glasgow Coma Scale score. Tracheostomy,
enteral nutrition, and the use of a subglottic secretion-drainage device were protective.
Conclusions: In patients with severe ARDS receiving lung-protective ventilation, VAP was associated with an
increased crude ICU mortality which did not remain significant after adjustment.
Introduction
Acute respiratory distress syndrome (ARDS) still carries
a high mortality rate. Ventilator-associated pneumonia
(VAP) is a complication of ARDS that may increase the
risk of multiple organ failure and death. However, the
impact of nosocomial pneumonia on mortality in
mechanically ventilated patients remains controversial
[1-4], and few data are available on mortality in ARDS
patients who experience VAP [5-10]. Moreover, many of
the studies related to VAP in ARDS patients were per-
formed before the use of lung-protective mechanical-
ventilation strategies. Modifications in mechanical-venti-
lation settings may have modified the epidemiology and
outcomes of VAP in patients with severe ARDS [11].
Here, we report the results of an epidemiologic study
performed in all patients included in a multicenter ran-
domized, placebo-controlled double-blind trial con-
ducted to determine whether briefly administering the
neuromuscular blocking agent (NMBA) cisatracurium
besylate early in the course of severe ARDS improved
the clinical outcomes. The results of this therapeutic
intervention have been reported elsewhere [12]. The
main objective of this prospective study was to deter-
mine whether bacterial VAP complicating severe ARDS
was associated with ICU death in patients receiving
lung-protective mechanical ventilation. We also deter-
mined the incidence and risk factors of VAP.
Materials and methods
Patients were enrolled from March 2006 through March
2008 at 20 French intensive care units [12]. The study
protocol was approved for all centers by the ethics
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committee of the Marseille University Hospital (Comité
Consultatif de Protection des Personnes dans la
Recherche Biomédicale Marseille 1, no 04/37). Accord-
ing to French law, written informed consent was
obtained from the patients or their surrogates.
Patients
Patients receiving endotracheal mechanical ventilation
for severe ARDS were eligible if the following criteria
were met for no more than 48 hours before enrollment:
ratio of partial pressure of arterial oxygen to fraction of
inspired oxygen (PaO2:FIO2) no greater than 150 mm
Hg at the time of enrollment, with a PEEP of at least 5
cm H2O and a tidal volume of 6 to 8 ml/kg, recent
appearance of bilateral pulmonary infiltrates consistent
with edema, and no evidence of left atrial hypertension.
Exclusion criteria were age younger than 18 years, lack
of consent, continuous infusion of NBMA, known
allergy to NMBA, known pregnancy, participation in
another trial within 30 days before meeting the eligibility
criteria, increased intracranial pressure, severe chronic
respiratory disease requiring long-term oxygen therapy
or home mechanical ventilation, actual body weight
exceeding 1 kg/cm of height, severe burns, severe
chronic liver disease (Child-Pugh class C), bone marrow
transplantation or chemotherapy-induced neutropenia,
pneumothorax, expected duration of mechanical ventila-
tion shorter than 48 hours, and decision to withhold
life-sustaining treatment.
Design
Suspected pneumonia was defined as the presence of
new or persistent radiographic features suggesting pneu-
monia without any other obvious cause and with two of
the following: fever > 38°C, leukocytosis (> 11.0 109/L)
or leukopenia (< 3.5 109/L), purulent endotracheal aspi-
rate, recent isolation of pathogenic bacteria from the
endotracheal aspirate [13], and increasing oxygen
requirements. These criteria had to be present more
than 2 days after ARDS onset. Bronchoalveolar lavage
(BAL) was done in the affected region of the lung iden-
tified on a chest radiograph. When PaO2:FIO2 was
lower than 80, protected minibronchoalveolar lavage
with a protected telescopic catheter could be performed.
Diagnosis of ventilator-associated pneumonia
In each ICU, an investigator made daily rounds to iden-
tify eligible patients and patients meeting criteria for
suspected VAP. VAP was diagnosed when a quantitative
culture of BAL fluid grew at least one bacterial organism
in a concentration ≥ 104 colony-forming units (CFU)/ml
or when mini-BAL fluid grew at least one bacterial
organism in a concentration ≥ 103 CFU/ml [14].
Definitions
Early-onset VAP complicating ARDS was defined as
pneumonia diagnosed between the third and seventh
days after ARDS onset. Late-onset VAP complicating
ARDS was defined as pneumonia diagnosed more than
7 days after ARDS. Patients were monitored for VAP
until their discharge from the ICU to a maximum of 90
days.
Empiric antibiotic therapy was started within a 24-
hour period after microbiologic samples were obtained
by BAL or protected telescoping catheter. Appropriate
empiric antibiotic therapy was defined as in vitro sus-
ceptibility to at least one antibiotic of the organism(s)
recovered from the BAL or the protected telescoping
catheter samples. However, if Pseudomonas sp. was iso-
lated, susceptibility to two drugs was required [15].
In patients with clinical and radiographic evidence of
deterioration after an initial improvement after a first
VAP, relapsing or recurrent infection was suspected if
the organism found initially was identified, and superin-
fection, if a different organism was found.
Data collection
Demographic data were collected. For the 24 hours
before randomization, we collected the physiological
variables, relevant therapeutic interventions, radio-
graphic findings, co-morbidities, and medications. Venti-
lator settings, physiological variables, radiographic
findings, and relevant therapeutic interventions were
recorded just before starting the study drug and then
24, 48, 72, and 96 hours later, and daily thereafter
between 6 a.m. and 10 a.m. until day 90 or hospital dis-
charge while breathing without assistance. Patients were
monitored daily for 28 days for signs of failure of non-
pulmonary organs and systems [16]. We recorded the
culture results, antibiotics used, duration of mechanical
ventilation, ICU-stay length, and hospital-stay length.
Throughout the ICU stay and until weaning off the ven-
tilator for patients without VAP or the diagnosis of VAP
for patients with VAP, we recorded daily the following
factors potentially associated with VAP: neuromuscular
blocking agent (NMBA) use during the first 48 hours,
enteral nutrition, stress-ulcer prophylaxis, tracheostomy,
transport out of the ICU (operating room, CT-scan),
subglottic secretion drainage, selective digestive deconta-
mination, emergency reintubation, prone positioning,
and renal replacement therapy.
Ventilation strategy
The volume-assist control mode was used, with a low
tidal volume of 6 ml/kg of predicted body weight. The
oxygenation goal was to maintain an arterial oxyhemo-
globin saturation measured by pulse oximetry of 88% to
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95% or a PaO2 of 55 to 80 mm Hg. This goal was
achieved by adjusting FIO2 and PEEP, as done in the
ARMA study [16]. The same ventilator-weaning proto-
col was used in both groups. Weaning was to be started
on day 3 if the FIO2 was no greater than 0.6.
Statistical analysis
We report means (± SD), relative risks with 95% confi-
dence intervals (CIs), and medians with interquartile
ranges (IQR) as appropriate. Differences between groups
were assessed by using the Student t test, Wilcoxon test,
c
2 analysis, or Fisher Exact test. We used the Wilcoxon
test to compare the numbers of ventilator-free days,
ICU-free days, and organ-failure-free days, all of which
had skewed distributions. All reported P values are two-
sided.
Kaplan-Meier curves were constructed to assess the
time from enrollment to death and to unassisted breath-
ing within 90 days.
To analyze the effect of VAP on ICU mortality, we
reported crude ICU mortality. We also performed a
logistic regression (forced-entry model) to identify fac-
tors independently associated with ICU death. We
planned to include all variables with P values < 0.20 by
univariate analysis. Colinearity also was assessed. The
occurrence of a VAP and the use of NMBA during the
first 48 hours of ARDS were also entered in the model.
In addition, we performed a multistate approach (clock-
forward multistate model) to take into account both the
time-dependence of the VAP and the presence of com-
peting risks (for example, ICU death and discharge alive
from the ICU) at each time point.
To identify risk factors for bacterial VAP, we also used
the clock-forward multistate model. Of the 11 variables
finally included in the model, seven had P values < 0.20
by univariate analysis (male sex, baseline Glasgow Coma
Scale score, emergency reintubation, tracheostomy,
transport out of the ICU, enteral nutrition, and subglot-
tic secretion drainage) and four were predefined covari-
ates (baseline SAPS II score, baseline PaO2:FIO2,
baseline respiratory system compliance, and continuous
NMBA use during the first 48 hours of ARDS).
All statistical analyses were performed by using PASW
Statistics software version 17 and R development Core
Team (2010). The multistage analysis was done by using
mstate package 0.2.6 (see Additional file 1) [17,18].
Results
Study population
Table 1 reports the main characteristics of the 339
severe ARDS patients. ARDS was caused by a direct
lung injury in 265 (78%) patients. The ICU mortality
rate was 33.9% (115 of 339). We found no clinically sig-
nificant differences between the groups with and
without VAP regarding the main baseline characteristics,
co-morbidities, or severity scores at ICU admission,
except for a significantly higher proportion of male
patients in the VAP group.
Incidence of ventilator-associated pneumonia
During the study period, 120 suspected first episodes of
bacterial VAP were evaluated by using BAL or mini-
BAL. A bacterial VAP was diagnosed in 98 (28.9%)
patients, with 26 cases of early-onset and 72 of late-
onset first VAP episode. In 69 patients, a single VAP
episode occurred. Twenty-two of the 98 patients had a
second episode of VAP, whereas five had three episodes,
and two had four episodes. A relapse or recurrent infec-
tion was diagnosed in six patients, and superinfections,
in 32 patients.
Median time on mechanical ventilation from ARDS
onset to the first VAP episode was 10 days (IQR, 6 to
17 days). Median time on mechanical ventilation from
endotracheal intubation to the first VAP episode was 11
days (IQR, 7 to 17 days). Most of the first VAP episodes
occurred within 3 weeks after ARDS onset. Figure 1
shows the cumulative probability of developing VAP
over time. The daily risk for developing bacterial VAP
increased until day 9 and then decreased throughout the
remainder of the ICU stay (Figure 2). The daily risk was
9% on day 7, 6% on day 12, and 3% on day 21.
In all, 112 bacterial strains grew in significant concen-
trations in BAL or protected mini-BAL specimens dur-
ing the first VAP episode. As indicated in Table 2, the
most common bacteria were nonfermenting, gram-nega-
tive bacilli (P. aeruginosa, Acinetobacter baumannii, and
Stenotrophomonas maltophilia) (40%) followed by Enter-
obacteriaceae (29%) and Staphylococcus aureus (21%).
Clinical outcomes
Mortality
The median time from VAP diagnosis to death was 8.5
days (IQR, 5.5 to 17 days). Of the 98 patients with VAP,
41 (41.8%; CI, 32.6% to 51.7%) died in the ICU, com-
pared with 74 (30.7%; CI, 25.2% to 36.8%) of the 241
patients without VAP (Table 3 and Figure 3) (P = 0.05).
In patients with early-onset VAP, mortality was 53.9%
(14 of 26 patients; CI, 35.5% to 71.3%), compared with
37.5% (27 of 72 patients; CI, 27.2% to 49.1%) in patients
with late-onset VAP (P = 0.15).
To determine whether VAP was an independent risk
factor for dying during the ICU stay in ARDS patients,
we performed a multiple logistic regression and a Cox
analysis by using a multistate model. As mentioned in
Table 4, age, male sex, plateau pressure on inclusion,
SOFA on inclusion, McCabe score, the systematic use of
NMBA, and the occurrence of VAP were entered into
the logistic regression model. The occurrence of a VAP
Forel et al. Critical Care 2012, 16:R65
http://ccforum.com/content/16/2/R65
Page 3 of 10
was not independently associated with the risk of ICU
death. With the multistate model, and after controlling
for the same risk factors, we were able to confirm that
the occurrence of a bacterial VAP was not associated
with the risk of ICU death (HR, 0.25; 95% CI from
0.003 to 23.5; P = 0.55). We conducted a post hoc analy-
sis excluding the patients who were not ventilated for at
least 9 days after inclusion (the first death in the VAP
Table 1 Characteristics of the 339 patients with severe acute respiratory distress syndrome
VAP
n = 98
No VAP
n = 241
P
value
Age, mean ± SD 60 ± 14 57 ± 16 0.10
Males, n (%) 79 (81%) 159 (66%) 0.009
Tidal volume (ml/kg predicted body weight), mean ± SDa 6.34 ± 0.95 6.59 ± 1.1 0.04
Minute ventilation (liters/minute), mean ± SDa 10.4 ± 2.4 9.9 ± 2.3 0.06
PEEP applied (cm of water), mean ± SDa 9.2 ± 3.3 9.2 ± 3.4 0.97
Plateau pressure (cm of water), mean ± SDa 25.4 ± 4.8 24.4 ± 4.8 0.11
Respiratory system compliance (ml/cm of water), mean ± SDa 30.2 ± 9.7 32.0 ± 11.1 0.15
FiO2, mean ± SD
a 0.77 ± 0.19 0.79 ± 0.19 0.43
pH, mean ± SDa 7.31 ± 0.10 7.32 ± 0.10 0.73
PaO2:FiO2, mean ± SD
a 106 ± 33 111 ± 40 0.24
PaCO2 (mm Hg), mean ± SD
a 47 ± 11 47 ± 11 0.66
SAPS II on admission, mean ± SD 50 ± 15 47 ± 15 0.19
SOFA on admission, mean ± SD 9.3 ± 3.8 9.3 ± 3.7 0.99
Glasgow Coma Scale score on admission, mean ± SD 10.9 ± 4.9 11.8 ± 4.2 0.08
Karnofsky score, mean ± SD 86 ± 14 88 ± 16 0.43
McCabe nonfatal, n (%) 74 (76%) 184 (76%) 0.99
Patients with immunodepression, n (%)
No 85 (87%) 192 (80%) 0.13
Chemotherapy 2 (2%) 20 (8%)
Long-term corticosteroids 4 (4%) 18 (7%)
HIV 2 (4%) 0 (0)
Other 3 (3%) 11 (5%)
Main reason for ICU admission, n (%)
Medical 68 (68%) 174 (72%) 0.60
Surgical emergency 18 (18%) 40 (17%) 0.75
Scheduled surgery 12 (12%) 27 (11%) 0.85
Corticosteroids for septic shock, n (%)a 40 (40%) 103 (43%) 0.81
Four radiologic quadrants involved, n (%)a 80 (82%) 196 (81%) 0.75
Direct lung injury, n (%)a 79 (81%) 186 (77%) 0.56
Primary cause of ARDS, n (%)a NS
Community-acquired pneumonia 33 (34) 97 (40)
Nosocomial pneumonia 21 (21) 36 (15)
Ventilator-associated pneumonia 6 (6) 8 (3)
Aspiration pneumonia 18 (18) 44 (18)
Lung contusion 2 (2) 2 (1)
Near-drowning 1 (1) 1 (0.5)
Smoke inhalation 0 (0) 1 (0.5)
Intraabdominal sepsis 7 (7) 23 (10)
Sepsis other 3 (3) 10 (4)
Acute pancreatitis 3 (3) 7 (3)
Multiple transfusion 3 (3) 3 (1)
Multiple trauma 2 (2) 2 (1)
Shock 5 (5) 11 (5)
Other 5 (5) 10 (4)
aOn inclusion. PEEP, positive end-expiratory pressure; SAPS II, Simplified Acute Physiology Score; SOFA, sequential organ-failure assessment; VAP, ventilator-
associated pneumonia.
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group occurred at day 10). Survival was higher in the
group of ARDS patients not developing a VAP (P =
0.038 by log-rank test). However, VAP was not asso-
ciated independently with death with a Cox regression
analysis with the same risk factors (P = 0.055).
Ventilator-free days
As indicated in Table 3, the numbers of ventilator-free
days from day 1 to day 28 and to day 90 were signifi-
cantly larger in patients without VAP than in patients
with VAP. The median duration of mechanical ventila-
tion was longer in patients with VAP who were alive on
day 90. As shown in Figure 4, patients without VAP
were disconnected earlier from the ventilator.
Adequacy of empiric antibiotic treatment
Empiric treatment was adequate in 95% of patients. The
mean duration of antibiotic treatment for VAP was 10.4
± 5.2 days overall and 11.3 ± 5.2 days in patients alive
at ICU discharge.
Risk factors for ventilator-associated pneumonia
By univariate analysis (Table 5), male sex and transport
out of the ICU were strongly associated with VAP. Both
consciousness alterations and enteral nutrition showed
trends toward associations with VAP. In contrast, VAP
was not associated with NMBA use, stress-ulcer prophy-
laxis (proton-pump inhibitors, sucralfate, H2-blockers, or
antacids), ARDS severity, or admission SAPS II score.
All factors listed in Table 6 were entered into the multi-
state model. Male sex, baseline Glasgow Coma Scale
score, tracheostomy (protective), enteral nutrition (pro-
tective), and the use of a subglottic secretion-drainage
system (protective) were independently associated with
VAP.
Discussion
Our study has three main findings. First, bacterial VAP
was diagnosed in approximately one third of patients with
severe ARDS. Second, VAP was associated with a higher
crude ICU mortality rate. However, no effect of VAP on
ICU mortality was found after adjustment. Third, male sex
and baseline Glasgow Coma Scale score were associated
with VAP in our patients with severe ARDS, whereas tra-
cheostomy, enteral nutrition, and the use of a subglottic
secretion-drainage system were protective.
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Figure 1 Kaplan-Meier estimates of the cumulative probability
of developing ventilator-associated pneumonia according to
the number of days on mechanical ventilation in the group of
98 patients with severe acute respiratory distress syndrome
who developed a ventilator-associated pneumonia.
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Figure 2 Hazard rate for ventilator-associated pneumonia over
time after the diagnosis of severe acute respiratory distress
syndrome. The hazard function evaluates the conditional
probability of ventilator-associated pneumonia on the next day in
an event-free patient. The hazard rate is the event rate per day over
the duration of mechanical ventilation.
Table 2 Microorganisms responsible for the first episode
of ventilator-associated pneumonia
n (% of VAPs)
Gram-negative bacilli
Pseudomonas aeruginosa 33 (34)
Escherichia coli 11 (11)
Enterobacter sp. 10 (10)
Proteus mirabilis 7 (7)
Stenotrophomonas maltophilia 5 (5)
Haemophilus sp. 3 (3)
Klebsiella sp. 4 (4)
Serratia sp. 3 (3)
Others 5 (5)
Gram-positive cocci
Methicillin-sensitive Staphylococcus aureus 12 (12)
Methicillin-resistant Staphylococcus aureus 9 (9)
Others 10 (10)
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Study rationale
Although several [6-10] studies evaluated the inci-
dence of VAP in patients with ARDS, only one [8]
sought to identify specific risk factors for VAP, and all
but one [8] used a single-center design. These studies
included 30 to 134 ARDS patients (Table 7). Much
more important, they were performed before the wide-
spread use of lung-protective ventilation. To our
knowledge, the epidemiology and outcomes of VAP
have not been evaluated in ARDS patients receiving a
strictly standardized protocol of lung-protective
mechanical ventilation [12]. This standardization is
important, as recent evidence indicates that cyclic
stretching of lung cells promotes bacterial growth
[11], suggesting that variations in the ventilation strat-
egy may affect the risk of VAP.
Incidence of ventilator-associated pneumonia
None of the patients received new antibiotics before
BAL or mini-BAL. Thus, the 28.9% incidence probably
reflects the incidence of bacterial VAP in our ARDS
patients, even if some suspicions were unconfirmed
(maybe some false-negatives existed). The main differ-
ence between our study and earlier studies [6-10] is that
the patients received lung-protective mechanical ventila-
tion according to a strict protocol.
Mortality and ventilator-associated pneumonia
The excess mortality potentially associated with VAP in
patients with severe ARDS is difficult to assess, because
many factors may contribute to death in such patients.
The management of ARDS has changed over the last
15-year period. Lung-protective mechanical ventilation
is now the standard of care. This change may contribute
to explaining the differences in ICU mortality between
our study (41.8% versus 30.7% with and without VAP,
respectively) and previously published studies [6-8] (52%
to 78% versus 59% to 92% with and without VAP,
respectively), which occurred despite similar baseline
severity scores (Table 7). However, improvements have
Table 3 Main outcome variables
VAP
% (95% CI)
no./total no.
No VAP
% (95% CI)
no./total no.
Relative risk (95%
CI)
P
value
Outcome
Primary
ICU mortality 41.8 (32.6-
51.7)
41/98
30.7 (25.2-
36.8)
74/241
1.36 (1.00-1.84) 0.05
Secondary
28-Day mortality 26.5 (18.8-
36.0)
26/98
29.0 (23.7-
35.1)
70/241
0.91 (0.62-1.34) 0.64
90-Day mortality 41.8 (32.6-
51.7)
41/98
33.6 (27.9-
39.8)
81/241
1.24 (0.93-1.67) 0.15
Ventilator-free days from day 1 to day 28 0 (0-10) 14 (0-21) 0.0001
Ventilator-free days from day 1 to day 90 50.5 (0-70) 76 (0-83) 0.0001
ICU-free days from day 1 to day 28 0 (0-0) 4 (0-16) 0.0001
ICU-free days from day 1 to day 90 32 (0-62) 66 (0-78) 0.0001
Days without failure of circulatory, coagulation, hepatic, and renal organs from day 1
to day 28
14.3 ± 10.4 14.0 ± 10.8 0.77
±, means ± SD. Differences between groups were assessed by using Student t test, Wilcoxon test, or c2 analysis. The number of ventilator-free days is the mean
number of days from day 1 to day 28 or day 90 with spontaneous breathing for at least 48 consecutive hours. CI, 95% confidence interval; NMBA, neuromuscular
blocking agent.
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Figure 3 Probability of survival through day 90 in patients
with and without ventilator-associated pneumonia.
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occurred in general ICU care and mortality in many
other critical illnesses during recent years.
Risk factors for VAP
Only male sex and the admission Glasgow Coma Scale
score were independently associated with an increased
risk of developing a bacterial VAP in our patients with
severe ARDS. In a study of 5,081 patients, Combes et al.
[19] found that nosocomial pneumonia was more com-
mon in men than in women (51% versus 44%; P = 0.01).
In a large US database including 9,080 patients, male
gender was an independent risk factor for VAP. Differ-
ences in VAP risk between men and women may be
related to differences in sex hormones [20], to sex-
related polymorphisms affecting immune responses to
bacterial agents [21], to differences in the distribution of
pathogens responsible for infections, to differences in
chronic comorbidities [22], and/or to differences in the
Table 4 Factors associated with ICU death by logistic regression
ICU survivors
n = 224
ICU nonsurvivors
n = 115
Univariate
unadjusted
P value
OR (CI 95%) Multivariate
adjusted
P value
Age (years), mean ± SD 55 ± 15 64 ± 14 0.0001 1.045 (1.026-1.063) 0.0001
Males, n (%) 151 (67.4) 87 (75.7) 0.12 1.469 (0.842-2.565) 0.18
Plateau pressure on inclusion (cm of water), mean ± SD 24.5 ± 4.7 25.2 ± 4.1 0.15 1.057 (1.000-1.116) 0.048
SOFA on inclusion, mean ± SD 9.6 ± 3.3 10.7 ± 3.5 0.006 1.132 (1.051-1.218) 0.001
NMBA, n (%) 125 (55.8) 52 (45.2) 0.065 0.568 (0.347-0.930) 0.024
VAP, n (%) 57 (25.4) 41 (35.7) 0.05 1.410 (0.833-2.386) 0.20
McCabe nonfatal, n (%) 179 (79.9) 79 (68.7) 0.022 0.592 (0.339-1.034) 0.066
CI 95%, 95% confidence interval for odds ratio; McCabe nonfatal, no death within 5 years; NMBA, neuromuscular blocking agent; OR, odds ratio; SOFA, sequential
organ-failure assessment; VAP, ventilator-associated pneumonia.
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Figure 4 Probability of breathing without assistance from the
day of inclusion to day 90.
Table 5 Risk factors potentially associated with VAP
VAP No VAP P value
Number (%) or mean ± SD Number (%) or mean ± SD
Age (years) 60 ± 14 57 ± 16 0.71
Male sex 79 (81) 159 (66) 0.006
Glasgow Coma Scale score on admission 10.9 ± 4.9 11.8 ± 4.2 0.09
SAPS II on inclusion 49 ± 15 49 ± 15 0.47
PaO2:FIO2 on inclusion 106 ± 33 111 ± 40 0.48
Respiratory system compliance on inclusion (ml/cm of water) 30 ± 10 32 ± 11 0.72
Received NMBA during the first 48 hours 48 (49) 129 (54) 0.36
Stress-ulcer prophylaxisa 81 (87) 206 (88) 0.80
Enteral nutritiona 80 (86) 179 (77) 0.09
Emergency reintubationa 18 (19) 28 (12) 0.11
Tracheostomya 30 (32) 53 (23) 0.15
Transport out of the ICUa 42 (45) 66 (28) 0.009
Subglottic secretion drainagea 11 (11) 44 (18) 0.14
Selective digestive decontaminationa 8 (9) 18 (8) 0.82
Corticosteroids for ARDSa 22 (22) 43 (18) 0.33
Vasopressora 91 (93) 215 (89) 0.31
Renal replacement therapy 37 (38) 81 (34) 0.47
Prone positiona 21 (21) 64 (27) 0.46
aPrior VAP (VAP group) or duration of mechanical ventilation + 2 days for the no-VAP group; NMBA, neuromuscular blocking agents; SAPS II, Simplified Acute
Physiology Score II; VAP, ventilator-associated pneumonia.
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level of care [23]. Severity of illness, and most notably
neurologic failure [24-29], is associated with an
increased risk of VAP. Finally, routine NMBA use dur-
ing the early phase of ARDS was not associated with the
risk of VAP. This is in contrast with some previous stu-
dies [25,30,31], in which NMBA use (for whatever dura-
tion) in nonselected mechanically ventilated ICU
patients was associated with a higher risk of VAP.
Study limitations
As stated in the ACURASYS study report [12], only 339
of 1,326 patients with severe ARDS assessed for eligibil-
ity were included. However, the vast majority of the
remaining 987 patients had exclusion criteria. The
strictly standardized ventilation protocol and strategy for
VAP diagnosis are major strengths of our study. Viral
pneumonia was not evaluated, as some of the participat-
ing centers did not routinely perform viral studies. A
study of the impact of viral infection on outcomes of
ARDS patients might be of interest.
Conclusions
In those with severe ARDS, patients ventilated according
to a standardized lung-protective strategy, the develop-
ment of VAP was associated with a higher risk for dying
in the ICU. However, no relation to ICU death was
found after adjustment.
Key messages
• In severe ARDS patients ventilated according to a
strictly standardized lung-protection strategy, VAP
increased crude ICU mortality.
• However, after adjustment, VAP did not remain
associated with ICU mortality.
• Factors independently associated with an increased
risk of acquiring VAP were male sex and admission
Glasgow Coma Scale score.
Additional material
Additional file 1: Multistate analysis procedure. Description of the
multistate model and syntax used in the mstate package 0.2.6 of R
development Core Team (2010).
Abbreviations
ARDS: acute respiratory distress syndrome; VAP: ventilator-associated
pneumonia; NMBA: neuromuscular blocking agent; PaO2:FIO2: ratio of partial
pressure of arterial oxygen to fraction of inspired oxygen; BAL:
bronchoalveolar lavage; (CFU)/ml: colony-forming units per milliliter; SAPS II:
Simplified Acute Physiology Score; SOFA: sequential organ failure
assessment.
Table 6 Risk factors associated with the occurrence of bacterial VAP
Hazard ratio 95% confidence interval for hazard ratio P
Lower Upper
Male sex 2.39 1.39 4.14 0.002
SAPS II on inclusion 0.99 0.97 1.00 0.14
Glasgow Coma Scale score on admission 0.93 0.88 0.98 0.01
PaO2:FIO2 on inclusion 0.99 0.99 1.00 0.54
Respiratory system compliance on inclusion 0.98 0.96 1.01 0.15
Received NMBA for 48 hours 1.03 0.69 1.54 0.88
Emergency reintubation 1.14 0.67 1.92 0.63
Tracheostomy 0.45 0.27 0.74 0.001
Transport out of the ICU 1.07 0.69 1.64 0.77
Enteral nutrition 0.56 0.33 0.97 0.04
Subglottic secretion drainage 0.52 0.27 0.99 0.05
Hazard ratios are for ventilator-associated pneumonia (VAP) versus no VAP by using the multistate model. NMBA, neuromuscular blocking agent.
Table 7 Main studies related to the epidemiology of VAP in ARDS patients
Patients, number Multicenter Standardized MV VAP incidence, % ICU mortality, % ICU mortality
VAP (%)/no VAP, (%)
Sutherland et al. (8) 105 No No 15 44 37.5/45
Delclaux et al. (6) 30 No No 60 83 78/92
Chastre et al. (5) 56 No No 55 61 52/72
Maduri et al. (9) 94 No No 43 - -
Markowicz et al. (7) 134 Yes No 23 58 57/59
VAP-ACURASYS 339 Yes Yes 29 34 42/31a
MV, mechanical ventilation; VAP, ventilator-associated pneumonia; aP < 0.05
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